<p>Revvity (RVTY) 已与赛诺菲建立战略联盟，开发和商业化一种用于早期检测 1 型糖尿病的新型大规模人群诊断检测。这标志着其现有罕见疾病领域的有意义扩展。</p>
<p>查看我们对 Revvity 的最新分析。</p>
<p>Revvity 的股价近期表现不佳，今天下跌了 3.7%，年初至今下跌了 21.2%，一年总股东回报率为 -27.2%。尽管近期的合作伙伴关系和产品发布表明增长的雄心依然存在，但投资者仍然保持谨慎，因为动能尚未显著逆转。</p>
<p>如果最新的医疗创新引起了你的关注，现在可能是探索该领域领导力和趋势的合适时机。查看完整列表，免费获取。</p>
<p>随着股价大幅下跌，公司交易价格低于分析师的目标价，现在的问题是 Revvity 是否为新投资者提供真正的上行空间，还是市场已经反映了其未来的增长潜力。</p>
<h2>最受欢迎的叙述：低估 23%</h2>
<p>最广泛关注的叙述将 Revvity 的公允价值评估为比其最后收盘价高出近 27 美元，未来盈利增长的乐观情绪与公司近期的市场挣扎形成鲜明对比。</p>
<blockquote>
<p><em>产品组合向更高利润率、软件驱动和消耗品驱动的产品（例如，SaaS Signals、试剂、新的 IDS i20 平台）持续转变，加上结构性成本措施，预计将显著扩大运营和净利润率。此外，2026 年的运营利润率基线将提高至 28%。</em></p>
</blockquote>
<p>阅读完整叙述。</p>
<p>想知道为什么分析师认为利润率在短短几年内可能会激增吗？这个公允价值的计算基于大胆的预测和利润率的跃升。揭示推动这一令人印象深刻的价格目标的财务假设和变化的组合。即使是怀疑者也可能会对潜在的预测感到惊讶。</p>
<p><strong>结果：公允价值为 115.19 美元（低估）</strong></p>
<p>完整阅读叙述，了解预测背后的原因。</p>
<p>然而，关键地区持续的市场疲软和持续的监管挑战可能会延迟任何有意义的复苏，并考验乐观预测的有效性。</p>
<p>了解与 Revvity 叙述相关的主要风险。</p>
<h2>另一种观点：基于比率的溢价风险</h2>
<p>从另一个角度看，Revvity 的市盈率目前为 36.8 倍。这高于美国生命科学行业平均水平 31.7 倍和公允比率 23.5 倍。这意味着，尽管预测了快速的盈利增长，但该股票的价格仍高于同行，并且市场可能最终会重新评估它。如果增长未能达到预期，这种溢价可能会对投资者构成风险吗？</p>
<p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/pe-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/pe-multiple-vs-industry"/></p>
<p>截至 2025 年 10 月 NYSE:RVTY 市盈率</p>
<h2>自定义你的 Revvity 叙述</h2>
<p>如果你想深入挖掘或得出自己的结论，可以在几分钟内使用 “按你自己的方式” 来整理 Revvity 前景的个性化视图。</p>
<p>一个好的起点是我们的分析，强调投资者对 Revvity 的 4 个关键回报的乐观情绪。</p>
<h2>寻找更多投资想法？</h2>
<p>在 Revvity 之外，还有一个充满智慧的机会世界。今天就掌控你的投资组合，解锁明日市场领导者的下一个增长浪潮。</p>
<ul>
<li>通过瞄准这些 19 只股息收益率超过 3% 的股票，来增加你的收入来源，这些公司提供来自财务稳健企业的有吸引力的收益。</li>
<li>通过研究这 24 只 AI 小盘股，站在科技创新的前沿，这些股票将受益于人工智能和机器学习的突破。</li>
<li>抓住被忽视的机会，利用这些 892 只基于现金流的低估股票，挖掘隐藏的潜力，这些股票的基本面强劲，交易价格低于其内在价值。</li>
</ul>
<p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>

赛诺菲集团

RVTY

赛诺菲

<p>Revvity (RVTY) 与赛诺菲合作开发一种新的诊断检测方法，以便早期检测 1 型糖尿病，扩展其在罕见疾病之外的关注点。尽管近期面临困难，股价当天下跌 3.7%，年初至今下跌 21.2%，分析师认为 Revvity 被低估，公允价值为 115.19 美元。然而，高市盈率和市场疲软的担忧对未来增长构成风险。投资者被鼓励在医疗行业持续挑战中探索 Revvity 的潜力</p>

<p>Revvity (RVTY) has entered into a strategic alliance with Sanofi to develop and commercialize a new population-scale diagnostic assay for early detection of type 1 diabetes. This marks a meaningful expansion from its existing rare disease footprint.</p>
<div class="lb-trans"><p>Revvity (RVTY) 已与赛诺菲建立战略联盟，开发和商业化一种用于早期检测 1 型糖尿病的新型大规模人群诊断检测。这标志着其现有罕见疾病领域的有意义扩展。</p>
</div><p>See our latest analysis for Revvity.</p>
<div class="lb-trans"><p>查看我们对 Revvity 的最新分析。</p>
</div><p>Revvity’s share price has struggled recently, down 3.7% for the day and 21.2% year-to-date, with a one-year total shareholder return of -27.2%. While recent partnerships and product launches suggest growth ambitions are alive, investors remain cautious as momentum has yet to meaningfully reverse.</p>
<div class="lb-trans"><p>Revvity 的股价近期表现不佳，今天下跌了 3.7%，年初至今下跌了 21.2%，一年总股东回报率为 -27.2%。尽管近期的合作伙伴关系和产品发布表明增长的雄心依然存在，但投资者仍然保持谨慎，因为动能尚未显著逆转。</p>
</div><p>If the latest healthcare innovation caught your attention, it could be the right time to explore leadership and trends in the sector. See the full list for free.</p>
<div class="lb-trans"><p>如果最新的医疗创新引起了你的关注，现在可能是探索该领域领导力和趋势的合适时机。查看完整列表，免费获取。</p>
</div><p>With shares down sharply and the company trading at a discount to analyst price targets, the question now is whether Revvity offers real upside for new investors or if the market already reflects its future growth potential.</p>
<div class="lb-trans"><p>随着股价大幅下跌，公司交易价格低于分析师的目标价，现在的问题是 Revvity 是否为新投资者提供真正的上行空间，还是市场已经反映了其未来的增长潜力。</p>
</div><h2>Most Popular Narrative: 23% Undervalued</h2>
<div class="lb-trans"><h2>最受欢迎的叙述：低估 23%</h2>
</div><p>With the most widely followed narrative assigning Revvity a fair value nearly $27 higher than its last close, optimism about future earnings growth stands in stark contrast to the company’s recent market struggles.</p>
<div class="lb-trans"><p>最广泛关注的叙述将 Revvity 的公允价值评估为比其最后收盘价高出近 27 美元，未来盈利增长的乐观情绪与公司近期的市场挣扎形成鲜明对比。</p>
</div><blockquote>
<p><em>Ongoing shift in product mix toward higher-margin, software-enabled and consumables-driven offerings (e.g., SaaS Signals, reagents, new IDS i20 platform), along with structural cost actions, are expected to materially expand operating and net margins. In addition, 2026 is set to start at a higher 28% operating margin baseline.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>产品组合向更高利润率、软件驱动和消耗品驱动的产品（例如，SaaS Signals、试剂、新的 IDS i20 平台）持续转变，加上结构性成本措施，预计将显著扩大运营和净利润率。此外，2026 年的运营利润率基线将提高至 28%。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>阅读完整叙述。</p>
</div><p>Want to know why analysts believe profit margins could surge in just a few years? The calculation behind this fair value rests on bold forecasts and margin leaps. Uncover the financial assumptions and shifting mix that fuel this impressive price target. Even skeptics might be surprised by the underlying projections.</p>
<div class="lb-trans"><p>想知道为什么分析师认为利润率在短短几年内可能会激增吗？这个公允价值的计算基于大胆的预测和利润率的跃升。揭示推动这一令人印象深刻的价格目标的财务假设和变化的组合。即使是怀疑者也可能会对潜在的预测感到惊讶。</p>
</div><p><strong>Result: Fair Value of $115.19 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>结果：公允价值为 115.19 美元（低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整阅读叙述，了解预测背后的原因。</p>
</div><p>However, ongoing market softness in key regions and persistent regulatory challenges could delay any meaningful recovery and test the validity of optimistic forecasts.</p>
<div class="lb-trans"><p>然而，关键地区持续的市场疲软和持续的监管挑战可能会延迟任何有意义的复苏，并考验乐观预测的有效性。</p>
</div><p>Find out about the key risks to this Revvity narrative.</p>
<div class="lb-trans"><p>了解与 Revvity 叙述相关的主要风险。</p>
</div><h2>Another View: Risk of Overpaying Based on Ratios</h2>
<div class="lb-trans"><h2>另一种观点：基于比率的溢价风险</h2>
</div><p>Looking from a different angle, Revvity’s price-to-earnings ratio is currently 36.8x. This is higher than both the US Life Sciences industry average of 31.7x and the fair ratio of 23.5x. This means that, despite forecasts of rapid earnings growth, the stock is more expensive than peers and where the market could eventually re-rate it. Could this premium become a risk for investors if growth falls short of expectations?</p>
<div class="lb-trans"><p>从另一个角度看，Revvity 的市盈率目前为 36.8 倍。这高于美国生命科学行业平均水平 31.7 倍和公允比率 23.5 倍。这意味着，尽管预测了快速的盈利增长，但该股票的价格仍高于同行，并且市场可能最终会重新评估它。如果增长未能达到预期，这种溢价可能会对投资者构成风险吗？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看数字对这个价格的看法——在我们的估值分析中了解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/pe-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/cdf799b7-9c94-432a-95de-7099ef88cf60/chart/pe-multiple-vs-industry"/></p>
<p>NYSE:RVTY PE Ratio as at Oct 2025</p>
<div class="lb-trans"><p>截至 2025 年 10 月 NYSE:RVTY 市盈率</p>
</div><h2>Build Your Own Revvity Narrative</h2>
<div class="lb-trans"><h2>自定义你的 Revvity 叙述</h2>
</div><p>If you want to dig deeper or come to your own conclusions, you can put together a personalized view of Revvity’s prospects in just a few minutes with Do it your way.</p>
<div class="lb-trans"><p>如果你想深入挖掘或得出自己的结论，可以在几分钟内使用 “按你自己的方式” 来整理 Revvity 前景的个性化视图。</p>
</div><p>A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Revvity.</p>
<div class="lb-trans"><p>一个好的起点是我们的分析，强调投资者对 Revvity 的 4 个关键回报的乐观情绪。</p>
</div><h2>Looking for More Investment Ideas?</h2>
<div class="lb-trans"><h2>寻找更多投资想法？</h2>
</div><p>There’s a world of smart opportunities beyond Revvity. Take control of your portfolio today and unlock the next wave of growth in tomorrow’s market leaders.</p>
<div class="lb-trans"><p>在 Revvity 之外，还有一个充满智慧的机会世界。今天就掌控你的投资组合，解锁明日市场领导者的下一个增长浪潮。</p>
</div><ul>
<li>Grow your income stream by targeting companies with reliable payouts using these 19 dividend stocks with yields &gt; 3%, offering attractive yields above 3% from financially solid businesses.</li>
<li>Position yourself at the forefront of tech innovation by researching these 24 AI penny stocks, set to benefit from breakthroughs in artificial intelligence and machine learning.</li>
<li>Jump on overlooked opportunities and uncover hidden potential with these 892 undervalued stocks based on cash flows, selected for strong fundamentals and trading below their intrinsic value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通过瞄准这些 19 只股息收益率超过 3% 的股票，来增加你的收入来源，这些公司提供来自财务稳健企业的有吸引力的收益。</li>
<li>通过研究这 24 只 AI 小盘股，站在科技创新的前沿，这些股票将受益于人工智能和机器学习的突破。</li>
<li>抓住被忽视的机会，利用这些 892 只基于现金流的低估股票，挖掘隐藏的潜力，这些股票的基本面强劲，交易价格低于其内在价值。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>这篇文章由 Simply Wall St 撰写，内容具有一般性。<strong>我们仅基于历史数据和分析师预测提供评论，采用无偏见的方法，我们的文章不构成财务建议。</strong> 它不构成买入或卖出任何股票的推荐，也不考虑你的目标或财务状况。我们的目标是为你提供以基本数据驱动的长期分析。请注意，我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中没有持仓。</em></p>
</div>

Revvity (RVTY)：在与赛诺菲结盟以扩大人口规模糖尿病诊断后评估其估值